Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05143905 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05143905 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 56 participants.
The verdict
NCT05143905, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study will evaluate safety, tolerability and pharmacokinetics (PK) of AZD7503, following subcutaneous (SC) administration of single ascending doses of AZD7503 in healthy participants.
Interventions
- DRUG Placebo
- DRUG AZD7503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2022-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05143905
The ClinicalTrials.gov registry entry for NCT05143905 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05143905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05143905 about?
NCT05143905 is a clinical study titled "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants". This study will evaluate safety, tolerability and pharmacokinetics (PK) of AZD7503, following subcutaneous (SC) administration of single ascending doses of AZD7503 in healthy participants.
What is the current status of trial NCT05143905?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2021-12-06. Estimated completion is 2022-11-09.
What interventions are being tested in trial NCT05143905?
The interventions under investigation include: Placebo (DRUG), AZD7503 (DRUG).
Who is sponsoring clinical trial NCT05143905?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.